Immune dysregulation and self-reactivity in schizophrenia: Do some cases of schizophrenia have an autoimmune basis?

Immunology and Cell Biology

Volumn 83, Issue 1, 2005, Pages 9-17

  Jones, Amanda L ^a   Mowry, Bryan J ^a   Pender, Michael P ^a,b   Greer, Judith M ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antibodies; Autoimmunity; Neurotransmitter receptors; Schizophrenia

Indexed keywords

AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT; NEUROTRANSMITTER RECEPTOR;

ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CYTAPHERESIS; HAPLOTYPE; HUMAN; IMMUNOREACTIVITY; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTAPHERESIS; MAJOR HISTOCOMPATIBILITY COMPLEX; NEUROTRANSMISSION; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW; SCHIZOPHRENIA; ULTRASTRUCTURE;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; RECEPTORS, NEUROTRANSMITTER; SCHIZOPHRENIA;

EID: 13144279297     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2005.01305.x     Document Type: Review

References (124)

1. Kraepelin E, Barclay RM, Robertson GM. Dementia Praecox and Paraphrenia. Edinburgh: E. & S. Livingstone, 1919.
2. Bleuler E. Dementia Praecox, or, the Group of Schizophrenias. New York: International Universities Press, 1950.
3. Liddle PF, Barnes TR, Morris D, Haque S. Three syndromes in chronic schizophrenia. Br. J. Psychiatry Suppl. 1989, 119-22.
4. Hornig M, Mervis R, Hoffman K, Lipkin WI. Infectious and immune factors in neurodevelopmental damage. Mol. Psychiatry 2002; 7: S34-5.
5. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry 1999; 46: 729-39.
6. Garbutt JC, van Kammen DP. The interaction between GABA and dopamine: implications for schizophrenia. Schizophr. Bull. 1983; 9: 336-53.
7. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987; 1: 133-52.
8. Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res. Brain Res. Rev. 2000; 31: 302-12.
9. Jones P, Cannon M. The new epidemiology of schizophrenia. Psychiatr. Clin. North Am. 1998; 21: 1-25.
10. Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev. 1995; 8: 131-45.
11. Noy S, Achiron A, Laor N. Schizophrenia and autoimmunity - a possible etiological mechanism? Neuropsychobiology 1994; 30: 157-9.
12. Fontana A, Storck U, Angst J, Dubs R, Abegg A, Grob PJ. An immunological basis of schizophrenia and affective disorders? Neuropsychobiology 1980; 6: 284-9.
13. Knight J, Knight A, Ungvari G. Can autoimmune mechanisms account for the genetic predisposition to schizophrenia? Br. J. Psychiatry 1992; 160: 533-40.
14. Amital H, Shoenfeld Y. Autoimmunity and schizophrenia: an epiphenomenon or an etiology? Isr. J. Med. Sci. 1993; 29: 593-7.
15. Ganguli R, Brar JS, Chengappa KN, Yang ZW, Nimgaonkar VL, Rabin BS. Autoimmunity in schizophrenia: a review of recent findings. Ann. Med. 1993; 25: 489-96.
16. Ganguli R, Brar JS, Rabin BS. Immune abnormalities in schizophrenia: evidence for the autoimmune hypothesis. Harv. Rev. Psychiatry 1994; 2: 70-83.
17. Wright P, Murray RM. Schizophrenia. Prenatal influenza and autoimmunity. Ann. Med. 1993; 25: 497-502.
18. Logan DG, Deodnar SD. Schizophrenia, an immunologic disorder? JAMA 1970; 212: 1703-4.
19. Kirch DG. Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr. Bull. 1993; 19: 355-70.
20. DeLisi LE, Crow TJ. Is schizophrenia a viral or immunologic disorder? Psychiatr. Clin. North Am. 1986; 9: 115-32.
21. Sirota P. Is schizophrenia an autoimmune disease? Isr. J. Med. Sci. 1990; 26: 694-7.
22. Abramsky O, Litvin Y. Autoimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia. Perspect. Biol. Med. 1978; 22: 104-14.
23. Mowry BJ, Nancarrow DJ. Molecular genetics of schizophrenia. Clin. Exp. Pharmacol. Physiol. 2001; 28: 66-9.
24. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363: 2063-72.
25. Rothermundt M, Arolt V, Bayer TA. Review of immunological and immunopathological findings in schizophrenia. Brain Behav. Immun. 2001; 15: 319-39.
26. Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M. T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc. Natl Acad. Sci. USA 2004; 101: 8180-5.
27. Naudin J, Mege JL, Azorin JM, Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 1996; 20: 269-73.
28. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr. Res. 2002; 57: 247-58.
29. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. Elevated interleukin-6 in schizophrenia. Psychiatry Res. 1999; 87: 129-36.
30. Shintani F, Kanba S, Maruo N et al. Serum interleukin-6 in schizophrenic patients. Life Sci. 1991; 49: 661-4.
31. Lin A, Kenis G, Bignotti S et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 1998; 32: 9-15.
32. Maes M, Meltzer HY, Bosnians E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 1994; 89: 346-51.
33. Muraguchi A, Hirano T, Tang B et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. 1988; 167: 332-44.
34. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur. J. Immunol. 1989; 19: 689-94.
35. Brett FM, Mizisin AP, Powell HC, Campbell IL. Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J. Neuropathol. Exp. Neurol. 1995; 54: 766-75.
36. Jun TY, Pae CU, Chae JH, Bahk WM, Kim KS, Han H. Polymorphism of CTLA-4 gene at position 49 of exon 1 may be associated with schizophrenia in the Korean population. Psychiatry Res. 2002; 110: 19-25.
37. Pullmann R, Lukac J, Skerenova M et al. Cytotoxic T lymphocyte antigen 4 (CTLA-4) dimorphism in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 1999; 17: 725-9.
38. Harbo HF, Celius EG, Vartdal F, Spurkland A. CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens 1999; 53: 106-10.
39. Burch PRJ. Schizophrenia: some new aetiological considerations. Br. J. Psychiatry 1964; 110: 818-24.
40. Witebsky E, Rose NR, Terplan K, Paine JR, Egan RW. Chronic thyroiditis and autoimmunization. JAMA 1957; 164: 1439-47.
41. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol. Today 1993; 14: 426-30.
42. Wright P, Sham PC, Gilvarry CM et al. Autoimmune diseases in the pedigrees of schizophrenic and control subjects. Schizophr. Res. 1996; 20: 261-7.
43. Gilvarry CM, Sham PC, Jones PB et al. Family history of autoimmune diseases in psychosis. Schizophr. Res. 1996; 19: 33-40.
44. Gorwood P, Pouchot J, Vinceneux P et al. Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. Schizophr. Res. 2004; 66: 21-9.
45. Othman SS, Abdul Kadir K, Hassan J, Hong GK, Singh BB, Raman N. High prevalence of thyroid function test abnormalities in chronic schizophrenia. Aust. NZ J. Psychiatiy 1994; 28: 620-4.
46. Gold MS, Sweeney DR. Perphenazine-induced systemic lupus erythematosus-like syndrome. J. Nerv. Ment. Dis. 1978; 166: 442-5.
47. Goldman LS, Hudson JI, Weddington WW Jr. Lupus-like illness associated with chlorpromazine. Am. J. Psychiatry 1980; 137: 1613-14.
48. Wickert WA, Campbell NR, Martin L. Acute severe adverse clozapine reaction resembling systemic lupus erythematosus. Postgrad. Med. J. 1994; 70: 940-1.
49. Nikkila HV, Muller K, Ahokas A, Rimon R, Andersson LC. Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr. Res. 2001; 49: 99-105.
50. Nikkila HV, Muller K, Ahokas A, Miettinen K, Rimon R, Andersson LC. Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am. J. Psychiatry 1999; 156: 1725-9.
51. Heath RG, Krupp IM. Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques. Arch. Gen. Psychiatry 1967; 16: 1-9.
52. Wright P, Donaldson PT, Underhill JA, Choudhuri K, Doherty DG, Murray RM. Genetic association of the HLA DRB1 gene locus on chromosome 6p21.3 with schizophrenia. Am. J. Psychiatry 1996; 153: 1530-3.
53. Wright P, Dawson E, Donaldson PT et al. A transmission/disequilibrium study of the DRB1*04 gene locus on chromosome 6p21.3 with schizophrenia. Schizophr. Res. 1998; 32: 75-80.
54. Grosskopf A, Muller N, Malo A, Wank R. Potential role for the narcolepsy- and multiple sclerosis-associated HLA allele DQB1*0602 in schizophrenia subtypes. Schizophr. Res. 1998; 30: 187-9.
55. Nimgaonkar VL, Rudert WA, Zhang X, Trucco M, Ganguli R. Negative association of schizophrenia with HLA DQB1*0602: evidence from a second African-American cohort. Schizophr. Res. 1997; 23: 81-6.
56. Sasaki T, Matsushita M, Nanko S, Fukuda R, Kennedy JL, Tokunaga K. Schizophrenia and the HLA-DRB1 gene in the Japanese population. Am. J. Psychiatry 1999; 156: 771-3.
57. Herbon N, Werner M, Braig C et al. High-resolution SNP scan of chromosome 6p21 in pooled samples from patients with complex diseases. Genomics 2003; 81: 510-18.
58. Lehmann-Facius H. Über die liquordiagnose der Schizophrenien. Klin. Wochenschr 1937; 16: 1646-8.
59. Heath R, Krupp I, Byers L, Liljekvist J. Schizophrenia as an immunologic disorder: 2. Effects of serum protein fractions on brain function. Arch. Gen. Psychiatry 1967; 16: 10-23.
60. Fessel WJ. Autoimmunity and mental illness. Arch. Gen. Psychiatry 1962; 6: 320-3.
61. Shima S, Yano K, Sugiura M, Tokunaga Y. Anticerebral antibodies in functional psychoses. Biol. Psychiatry 1991; 29: 322-8.
62. Heath RG, McCarron KL, O'Neil CE. Antiseptal brain antibody in IgG of schizophrenic patients. Biol. Psychiatiy 1989; 25: 725-33.
63. Henneberg AE, Horter S, Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr. Res. 1994; 14: 15-22.
64. Teplizki HA, Sela B, Shoenfeld Y. Autoantibodies to brain and polynucleotides in patients with schizophrenia: a puzzle. Immunol. Res. 1992; 11: 66-73.
65. Knight JG, Knight A, Menkes DB, Mullen PE. Autoantibodies against brain septal region antigens specific to unmedicated schizophrenia? Biol. Psychiatry 1990; 28: 467-74.
66. Yang ZW, Chengappa KN, Shurin G et al. An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia. Psychol. Med. 1994; 24: 449-55.
67. Pelonero A, Pandurangi A, Calabrese V. Autoantibodies to brain lipids in schizophrenia. Am. J. Psychiatry 1990; 147: 661-2.
68. Stevens A, Weller M. Ganglioside antibodies in schizophrenia and major depression. Biol. Psychiatry 1992; 32: 728-30.
69. Knight JG. Dopamine-receptor-stimulating autoantibodies: a possible cause of schizophrenia. Lancet 1982; 2: 1073-6.
70. Borda T, Perez Rivera R, Joensen L, Gomez RM, Sterin-Borda L. Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J. Immunol. 2002; 168: 3667-74.
71. Fudenberg HH, Whitten HD, Merler E, Farmati O. Is schizophrenia an immunologic receptor disorder? Med. Hypotheses 1983; 12: 85-93.
72. Borda T, Gomez R, Berria MI, Sterin-Borda L. Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera. Glia 2004; 45: 144-54.
73. Tanaka S, Matsunaga H, Kimura M et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J. Neuroimmunol. 2003; 141: 155-64.
74. Mukherjee S, Mahadik SP, Korenovsky A, Laev H, Schnur DB, Reddy R. Serum antibodies to nicotinic acetylcholine receptors in schizophrenic patients. Schizophr. Res. 1994; 12: 131-6.
75. Chengappa K, Yang Z, Schurin G, Farooqui SM, Rabin B, Ganguli R. Antibodies to D-2 receptor in neuroleptic-naive schizophrenic patients. Biol. Psychiatry 1993; 33 (Suppl.): 97A.
76. Spivak B, Radwan M, Bartur P, Mester R, Weizman A. Anti-nuclear autoantibodies in chronic schizophrenia. Acta Psychiatr. Scand. 1995; 92: 266-9.
77. Sirota P, Firer MA, Schild K et al. Autoantibodies to DNA in multicase families with schizophrenia. Biol. Psychiatry 1993; 33: 450-5.
78. Johnstone EC, Whaley K. Antinuclear antibodies in psychiatric illness: their relationship to diagnosis and drug treatment. Br. Med. J. 1975; 2: 724-5.
79. Ganguli R, Rabin BS, Brar JS. Antinuclear and gastric parietal cell autoantibodies in schizophrenic patients. Biol. Psychiatry 1992; 32: 735-8.
80. Zorrilla EP, Cannon TD, Gur RE, Kessler J. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease? Biol. Psychiatry 1996; 40: 825-33.
81. Rudin DO. The choroid plexus and system disease in mental illness. I. A new brain attack mechanism via the second blood-brain barrier. Biol. Psychiatry 1980; 15: 517-39.
82. Vetlugina TP, Logvinovich GV, Maslennikova SN, Vasil'eva OA. [Circulating immune complexes in the serum of mental patients and healthy subjects.] Zh. Nevropatol. Psikhiatr. Im. S. S. Korsakova 1984; 84: 422-6.
83. Schulz SC, van Kammen DP, Waters R, Klein HG, Balow JE, Bunney WE Jr. Double-blind evaluation of plasmapheresis in schizophrenic patients: a pilot study. Artif. Organs 1983; 7: 317-21.
84. Valbonesi M, Garelli S. Plasma exchange in neurological diseases. A critical approach. Vox. Sang. 1983; 44: 65-80.
85. Levine J, Gutman J, Feraro R et al. Side effect profile of azathioprine in the treatment of chronic schizophrenic patients. Neuropsychobiology 1997; 36: 172-6.
86. Leykin I, Mayer R, Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 1997; 37: 75-86.
87. Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum. 1996; 39: 2035-45.
88. Hanly JG, Liang MH. Cognitive disorders in systemic lupus erythematosus. Epidemiologic and clinical issues. Ann. NY Acad. Sci. 1997; 823: 60-8.
89. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 2001; 7: 1189-93.
90. Garey RE, Heath RG, Harper JW. Focal electroencephalographic changes induced by anti-septal antibodies. Biol. Psychiatry 1974; 8: 75-88.
91. Bergen JR, Grinspoon L, Pyle HM, Martinez JL, Pennell RB. Immunologic studies in schizophrenic and control subjects. Biol. Psychiatry 1980; 15: 369-79.
92. Vilkov GA, Bardakhch'ian EA, Stepanenko EM, Siletskii O. [Ultrastructural and biochemical evidence of brain damage by the serum IgG fraction of the blood of schizophrenics.] Zh. Nevropatol. Psikhiatr. Im. S. S. Korsakova 1984; 84: 767-70.
93. Bacman S, Sterin-Borda L, Camusso JJ, Hubscher O, Arana R, Borda ES. Circulating antibodies against neurotransmitter receptor activities in children with congenital heart block and their mothers. FASEB J. 1994; 8: 1170-6.
94. Whitney KD, McNamara JO. Autoimmunity and neurological disease: antibody modulation of synaptic transmission. Annu. Rev. Neurosci. 1999; 22: 175-95.
95. Cavill D, Waterman SA, Gordon TP. Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission. Arthritis Rheum. 2003; 48: 3597-602.
96. Lang B, Dale RC, Vincent A. New autoantibody mediated disorders of the central nervous system. Curr. Opin. Neurol. 2003; 16: 351-7.
97. Whitney KD, McNamara JO. GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. J. Neurosci. 2000; 20: 7307-16.
98. Lang B, Newsom-Davis J. Immunopathology of the Lambert-Eaton myasthenic syndrome. Springer Semin. Immunopathol. 1995; 17: 3-15.
99. Takamori M, Komai K, Iwasa K. Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome. Am. J. Med. Sci. 2000; 319: 204-8.
100. Reid DM, Perry VH, Andersson PB, Gordon S. Mitosis and apoptosis of microglia in vivo induced by an anti-CR3 antibody which crosses the blood-brain barrier. Neuroscience 1993; 56: 529-33.
101. Knopf PM, Harling-Berg CJ, Cserr HF et al. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J. Immunol. 1998; 161: 692-701.
102. Hickey WF. Basic principles of immunological surveillance of the normal central nervous system. Glia 2001; 36: 118-24.
103. Korschenhausen DA, Hampel HJ, Ackenheil M, Penning R, Muller N. Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr. Res. 1996; 19: 103-9.
104. Nikkila HV, Ahokas A, Wahlbeck K, Rimon R, Andersson LC. Neopterin and macrophage inflammatory protein-1alpha in the cerebrospinal fluid of schizophrenic patients: no evidence of intrathecal inflammation. Neuropsychobiology 2002; 46: 169-72.
105. Schwarz MJ, Ackenheil M, Riedel M, Muller N. Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neurosci. Lett. 1998; 253: 201-3.
106. Rieckmann P, Nunke K, Burchhardt M et al. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. J. Neuroimmunol. 1993; 47: 133-40.
107. Ben-Shachar D, Livne E, Spanier I, Leenders KL, Youdim MB. Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeC13 uptake. J. Neurochem. 1994; 62: 1112-18.
108. Muller N, Ackenheil M. Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology. Schizophr. Res. 1995; 14: 223-8.
109. Kirch DG, Kaufmann CA, Papadopoulos NM, Martin B, Weinberger DR. Abnormal cerebrospinal fluid protein indices in schizophrenia. Biol. Psychiatry 1985; 20: 1039-46.
110. Bauer K, Kornhuber J. Blood-cerebrospinal fluid barrier in schizophrenic patients. Eur. Arch. Psychiatry Neural. Sci. 1987; 236: 257-9.
111. Kirch DG, Alexander RC, Suddath RL et al. Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia. J. Neural Transm. Gen. Sect. 1992; 89: 219-32.
112. Pandey RS, Gupta AK, Chaturvedi UC. Autoimmune model of schizophrenia with special reference to antibrain antibodies. Biol. Psychiatry 1981; 16: 1123-36.
113. DeLisi LE, Weber RJ, Pert CB. Are there antibodies against brain in sera from schizophrenic patients? Review and prospectus. Biol. Psychiatry 1985; 20: 110-15.
114. Whittingham S, Mackay I, Jones IH, Davies B. Absence of brain antibodies in patients with schizophrenia. Br. Med. J. 1968; 1: 347-8.
115. Sundin U, Thelander S. Antibody reactivity to brain membrane proteins in serum from schizophrenic patients. Brain Behav. Immun. 1989; 3: 345-58.
116. Schott K, Batra A, Richartz E et al. Antibrain antibodies in mental disorder: no evidence for antibodies against synaptic membranes. J. Neural Transm. 1998; 105: 517-24.
117. Kelly RH, Ganguli R, Rabin BS. Antibody to discrete areas of the brain in normal individuals and patients with schizophrenia. Biol. Psychiatry 1987; 22: 1488-91.
118. Plioplys AV, Thibault J, Bouchard JP, Cockburn C, Hawkes R. Anti-CNS antibodies in neurological and psychiatric disorders. J. Neurol. Neurosurg. Psychiatry 1987; 50: 1514-21.
119. Ganguli R, Rabin BS, Kelly RH, Lyte M, Ragu U. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann. NY Acad. Sci. 1987; 496: 676-85.
120. Mellsop G, Whittingham S, Ungar B. Schizophrenia and autoimmune serological reactions. Arch. Gen. Psychiatry 1973; 28: 194-6.
121. Chengappa KN, Carpenter AB, Keshavan MS et al. Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biol. Psychiatry 1991; 30: 731-5.
122. Kim JJ, Lee SJ, Toh KY, Lee CU, Lee C, Paik IH. Identification of antibodies to heat shock proteins 90 kDa and 70 kDa in patients with schizophrenia. Schizophr. Res. 2001; 52: 127-35.
123. Kilidireas K, Latov N, Strauss DH et al. Antibodies to the human 60 kDa heat-shock protein in patients with schizophrenia. Lancet 1992; 340: 569-72.
124. Shinitzky M, Deckmann M, Kessler A, Sirota P, Rabbs A, Elizur A. Platelet autoantibodies in dementia and schizophrenia. Possible implication for mental disorders. Ann. NY Acad. Sci. 1991; 621: 205-17.